The Global Blood Glucose Monitoring Devices Market has witnessed continuous growth in the last few years and is projected to grow even further during the forecast period of 2024-2033. The assessment provides a 360° view and insights - outlining the key outcomes of the Blood Glucose Monitoring Devices market, current scenario analysis that highlights slowdown aims to provide unique strategies and solutions following and benchmarking key players strategies. In addition, the study helps with competition insights of emerging players in understanding the companies more precisely to make better informed decisions.

Browse for Full Report at @ https://www.thebrainyinsights.com/report/blood-glucose-monitoring-devices-market-13672

Company references (brand → reported values / notes)
Abbott (FreeStyle Libre / Diabetes Care) — Diabetes Care revenue: $6.8 billion (full-year 2024). Abbott reported FreeStyle Libre sales growth and Diabetes Care at ~$6.8B for 2024.

Dexcom (CGM) — Revenue: ~$4.03 billion (2024). Dexcom reported ~ $4.03B revenue for fiscal 2024.

Roche (Accu-Chek / Roche Diabetes Care) — Roche Group strong 2024 sales; Roche Diabetes Care is a multi-hundred-million to low-billion USD business (market sources list Roche Diabetes Care among top providers; some estimates list ~ $1.5B range in prior year reporting). (Roche reports consolidated results — diabetes care is within Diagnostics/Diabetes reporting).

Medtronic Diabetes — Reported diabetes/insulin-delivery & glucose monitoring revenues in the multi-hundreds of millions to low billions (corporate reporting shows Medtronic Diabetes as a ~$2B-range business in recent public summaries).

Ascensia Diabetes Care (Contour) — Large BGM (blood glucose meter) & strip supplier — industry estimates place annual revenue in the hundreds of millions (varies by source; Ascensia is a leading BGM supplier globally).

LifeScan / OneTouch — historically a billion-dollar+ BGM franchise (OneTouch). Recent: LifeScan (Platinum Equity–owned) filed bankruptcy restructuring in 2025 (significant market event impacting BGM supply/ownership).

Senseonics (Eversense) — 2024 revenue: ~$22.5 million (small, niche implantable CGM specialist).

Note: many parent companies (Roche, Medtronic) report consolidated figures — brand-level revenues are sometimes reported separately (Abbott, Dexcom are the cleanest brand-level public numbers). When brand numbers aren’t available, I cite parent company reporting or specialist press estimates.

Market sizing & segmentation (selected estimates)
Overall Blood Glucose Monitoring / Diabetes devices market: estimates vary by scope and source. Examples:

Broad diabetes care devices market (monitoring + delivery) cited at ~$64.5B (2024) by one source with projections to expand strongly.

Blood glucose monitoring / BGM + CGM focused estimates: some reports estimate BGMs + CGMs market in the mid-teens of billions (e.g., $12–24B range in 2024–2025) depending on whether insulin delivery & services are included. Grand View estimates the CGM market alone at ~$13.66B (2024).

Recent developments (high-impact)
Rapid CGM growth & product launches (Abbott FreeStyle Libre expansion, Dexcom G7/G7-variants, longer-wear sensors). Abbott and Dexcom continued major product rollouts in 2024–2025.

Regulatory / market access shifts — OTC/retail access expansions and reimbursement updates are enabling wider CGM adoption beyond type-1 diabetes to type-2, prediabetes and metabolic tracking.

Major corporate events: LifeScan (OneTouch) entered a court-supervised restructuring (bankruptcy) in 2025, a notable change in BGM market structure.

Drivers
Clinical effectiveness of CGM (improved glycemic outcomes → clinician & payer acceptance).

Broader indications & reimbursement expansion (type-2, remote monitoring, telehealth integration).

Consumer & wearable health trends (connected health, consumer interest in metabolic data, partnerships with consumer wearables/health apps).

Rising diabetes prevalence globally — demographic & lifestyle factors increase demand for monitoring devices.

Restraints
Cost & reimbursement variability (CGMs are more expensive than strip-based BGMs; unequal payor coverage restrains uptake in some markets).

Competitive pricing & commoditization for test strips/meters (pressure on legacy BGM players).

Regulatory hurdles for new sensor types and non-invasive monitoring (accuracy and approval challenges).

Regional segmentation analysis
North America — largest / most mature market (strong CGM penetration, favorable reimbursement environment).

Europe — mature adoption with sizeable public payer markets; regulatory pathways active for expanded CGM indications.

Asia-Pacific — fastest growth (rising prevalence, increasing access, local manufacturers / low-cost strips play a role). China, India, Japan & Korea are primary growth engines.

Emerging trends
Consumer/fitness integration — CGM data used by non-diabetic consumers for metabolic health (partnerships with wearables/health apps).

Longer-wear & implantable CGMs (e.g., Senseonics Eversense 365) and extended sensor life.

Lower-cost sensors / competitive pricing as manufacturers scale and new entrants push prices down.

AI & analytics on glucose data (value-added services, predictive alerts, nutritional/behavioural insights).

Top use cases
Type-1 diabetes management (real-time CGM + insulin dosing).

Insulin-treated type-2 diabetes (glycemic control & hypoglycaemia prevention).

Non-insulin users / metabolic monitoring (wellness applications, research).

Hospital / inpatient glucose monitoring & point-of-care systems (specialist devices).

Major challenges
Reimbursement & payer fragmentation across markets limiting uniform adoption.

Accuracy, user trust, and clinical integration — clinicians must trust data for dosing decisions.

Supply chain & pricing pressure on strip/consumable businesses (legacy BGM makers face margin pressure).

Attractive opportunities
Expanding CGM into broader populations (type-2, maternity/GDM, prediabetes/metabolic health).

Value-added digital services & subscription models (analytics, coaching, telehealth).

Emerging markets (APAC, LATAM) — rising prevalence and improved payer frameworks.

Long-wear / implantable sensors & combination devices (differentiation vs commodity meters).

Key factors of market expansion
Reimbursement policies & guideline updates that broaden CGM coverage.

Device innovation improving accuracy, wearability, and sensor life (drives clinical & consumer uptake).

Integration with digital health ecosystems (apps, remote monitoring, telemedicine).

Price competition & scale for consumables (reducing cost barriers)

Primary sources used (selected)
Abbott corporate reporting / Diabetes Care disclosure (Abbott FY-2024).

Dexcom financials & 2024 Annual Report.

Grand View Research — CGM market sizing.

Fortune Business Insights / industry reports listing major players.

WSJ / news coverage — LifeScan bankruptcy / restructuring (July 2025).

Senseonics financial release (Eversense / implantable CGM).

If you’d like, I can next (pick one):

convert this into a 1-page PowerPoint slide with the company table and cited callouts; or

produce an Excel table listing the companies, their most recent reported revenues (with source links), product focus (BGM vs CGM vs implantable), and public/private status; or

expand competitor profiles with FY revenue breakdowns, product launches (last 18 months), and market share estimates.

Tell me which output you want and I’ll produce it now (slide / Excel / competitor deep-dive).